Take action now!
Our goal: Pfizer & GSK to lower the price of the vaccine against pneumonia to $5 per child in all developing countries, giving all kids a fair shot 👇
2,500 kids die each day from #pneumonia. Demand @Pfizer & @GSK lower the price of the pneumonia vaccine to $5/child for all developing countries #AskPharma
Thank you for helping us #AskPharma to lower the price of the pneumonia vaccine! Over 416,272 people from 170 countries signed our petition, which was handed to Pfizer and GSK in New York, London, and Madrid.
On April 27, 2016, we carried your voices to Pfizer Headquarters, and they accepted our petition. Thanks to your actions agreements are now in place with Pfizer and GSK for humanitarian organizations like MSF to obtain lowest global price for PCV, around US$9 per child (for all three doses).
Thank you for helping us raise the pressure! This campaign is not over, we are still asking Pfizer and GSK to lower the prices of the vaccine to $5 per child for all developing countries.
HERE'S WHY YOU SHOULD CARE
Pfizer and GlaxoSmithKline (GSK) are the only two producers of the life-saving pneumonia vaccine. Many lives have been saved by this vaccine, but pneumonia still kills nearly 1 million children every year.
In fact, 75% of children around the world remain unprotected against pneumonia, the leading infectious cause of childhood death worldwide.
You have the power to help change this.
Only about half of the world’s countries have been able to start using the pneumonia vaccine produced by Pfizer & GSK, known as the pneumococcal conjugate vaccine (PCV). One key barrier is the high price.
Even at the lowest global prices, it costs 68 times more today to vaccinate a child in developing countries than it did in 2001 – nearly half of that increase is due to the high price of the pneumonia vaccine alone. This means that a growing number of developing countries can't afford to buy the pneumonia vaccine to protect their children against this childhood killer.
Pfizer & GSK have collectively reported nearly US$48 billion in global sales from this vaccine. That’s almost three times the entire 20-year budget that Gavi, the Vaccine Alliance, uses to provide 10 different vaccines in around 60 of the world’s poorest countries.
In 2016 after years of efforts and public campaigning Pfizer and GSK finally announced that they were reducing the price of the vaccine to slightly more than 9 US dollars per child for humanitarian organisations like MSF. While this is definitely a step in the right direction, it means that millions of children are still left unvaccinated in countries where their parents or governments can’t afford the vaccine.
It's time for Pfizer and GSK to lower the price to $5 per child (for all three doses) for all developing countries.
The lowest global price for the pneumonia vaccine is just over $9 per child (for all three doses), available to only the poorest countries through Gavi. History has shown that with competition, prices will inevitably come down. A producer in India is developing a pneumonia vaccine that it has promised to sell for $6 per child – but it won’t be available until at least 2019. A more affordable pneumonia vaccine could help reduce this unnecessary loss of life, so why wait any longer to lower the price?
Please help us ask Pfizer & GSK to put children's lives over more blockbuster revenues. Today, children are being left unprotected in countries such as Indonesia, Iraq, Jordan, Lebanon, Romania, Syria and Thailand, among many others. A child dies of pneumonia every 35 seconds.
Now's the time to lower the price of the pneumonia vaccine to $5 per child (for all three doses) for all developing countries, so more lives can be saved.
Together we can do this.
NOVEMBER 2018 UPDATE
Well over half a million people trapped in humanitarian emergencies have now received the pneumonia vaccine since GSK and Pfizer finally agreed to reduce the price of their vaccine for humanitarian organisations in 2016. Since 2017, a Humanitarian Mechanism has allowed 613,000 doses to be purchased at the reduced price of about US$9 per child (for all three doses). Through this mechanism, MSF has used 360,000 doses in 12 emergency vaccination interventions in Central African Republic, Nigeria, Niger, South Sudan, and Syria.
But the Humanitarian Mechanism is limited in scope as it can only be used by humanitarian organisations. Developing countries are left out as they are unable to access the pneumonia vaccine at this reduced price. Many children in developing countries are therefore left unprotected from preventable, life-threatening pneumonia. That’s why we’re still demanding that GSK and Pfizer reduce the price of the pneumonia vaccine to US$5 per child for all developing countries.
APRIL 2018 UPDATE
Did you know that MSF is fighting Pfizer in court?
One reason that the pneumococcal conjugate vaccine (PCV) is too expensive for many countries to use is a lack of competition in the vaccines market.
Pfizer, which has the largest share of the pneumonia vaccines market, is trying to extend its monopoly and maximise its profits by securing additional, unmerited patents to protect its vaccine intellectual property. For example in South Korea and India, Pfizer has sought, and been granted, a patent on their pneumonia vaccine which means other companies will be blocked from making more affordable versions for years to come.
It’s a scandal. We are fighting Pfizer in court in India and supporting a similar court case in South Korea.
The case against Pfizer is strong: the patents they are seeking are not justified. This tactic is part of its wider ‘evergreening’ strategy: the company makes inconsequential changes to their vaccine to secure additional patents to extend their monopoly and increase their profits. In fact these patents have already been refused or challenged in other countries.
We will not back down while children’s lives are at stake. We're calling on Pfizer to stop blocking cheaper pneumonia vaccines and help give children around the world #AFairShot. Help us spread the word by clicking here to share our content on Facebook or click here to share on Twitter. Thank you for your support!
JULY 2017 UPDATE
After years of public pressure, GSK and Pfizer finally agreed to lower the price of their pneumonia vaccines for humanitarian organisations in October and November 2016, respectively. In May 2017, MSF, WHO, UNICEF and Save the Children established a Humanitarian Mechanism for vaccinating in emergencies (Accessing Affordable and Timely Supply of Vaccines for use in Humanitarian Emergencies: the Humanitarian Mechanism). Pneumococcal conjugate vaccines (PCV) are the first vaccines to be included in this Humanitarian Mechanism.
MSF signed bilateral supply agreements with Pfizer and GSK in July 2017 for their pneumonia vaccines. MSF is now purchasing pneumonia vaccines from Pfizer and GSK under the terms of the Humanitarian Mechanism and within the scope of our purchase agreements with both companies. In 2017, we vaccinated children in Central African Republic, Niger, Nigeria, South Sudan and Syria, helping to protect them from life-threatening pneumonia.
FEBRUARY 2017 UPDATE
To our A Fair Shot supporters wondering how the progress is going with GSK and Pfizer, we have an update for you! In September and November 2016, GSK and Pfizer (respectively) made commitments to offer humanitarian organisations working in emergencies the lowest global price for the pneumonia vaccine. More than 3 months have passed since the companies made their announcements. As of late February 2017, negotiations with both companies are just beginning. We hope that Pfizer and GSK will deliver on their promises and make the pneumonia vaccine available to children living in emergency contexts as soon as possible.
FEBRUARY 14, 2017
After years of negotiation, Pfizer finally announced in November 2016 that it was reducing the price of its pneumococcal conjugate vaccine, Prevenar 13, (PCV13) to 3.10 per dose (US$ 9.30 per child for all three doses) for humanitarian organisations working in emergency settings. This is definitely a step in the right direction and will help to protect millions of vulnerable children around the world and in MSF projects. We now hope that Pfizer will extend its efforts to developing countries by offering a lower price to all governments which still can’t afford to protect their children against pneumonia. Read More